Therapeutic Focus Areas

With more than 350 scientists dedicated to new chemical entity (NCE) research and more than 100 scientists involved in new biologic entity (NBE) research, we have developed an enviable and robust pipeline focused in oncology, dermatology and respiratory. Our efforts are anchored in first- and best-in-class discovery. With 5 NBEs and 3 NCEs in various stages of clinical development, Glenmark is delivering on its commitment to bring the best science to patients worldwide.

Click here to view our innovative pipeline.